Long acting injectable HIV treatment offers an alternative to daily oral medication for eligible people living with HIV. These treatments use injections administered at scheduled intervals to maintain medication levels and suppress viral activity. Understanding available options, eligibility requirements, administration schedules, potential side effects, and medical monitoring helps individuals make informed decisions with their healthcare providers.
One widely used option combines cabotegravir and rilpivirine, marketed as Cabenuva. Cabotegravir belongs to a medication class called integrase strand transfer inhibitors, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, these medicines prevent HIV from multiplying through different mechanisms.
Unlike traditional daily oral antiretroviral therapy, injectable treatment follows a scheduled administration plan. However, it is not suitable for everyone. Healthcare professionals evaluate treatment history, viral suppression, resistance information, and other medical considerations before recommending this approach.
Important features of injectable HIV treatment include:
Medication combination: Cabotegravir and rilpivirine work together to prevent HIV replication.
Administration schedule: Injections are generally administered every month or every two months, depending on the prescribed schedule.
Treatment eligibility: Candidates generally need to have an undetectable or suppressed viral load and no known or suspected resistance to either medication.
Medical supervision: Healthcare professionals administer the injections and monitor treatment response.
Treatment continuity: Maintaining scheduled appointments is important for keeping medication levels effective.
Long acting injectable HIV treatment options have expanded the ways eligible individuals can manage HIV. Cabotegravir and rilpivirine are currently an established long acting injectable combination for HIV treatment. Another injectable medication, lenacapavir, has a different role in HIV care and is used for treatment in combination with other antiretroviral medicines in certain circumstances.
Lenacapavir is a capsid inhibitor that can be administered every six months as part of a combination treatment regimen for people with multidrug-resistant HIV whose infection is not adequately controlled with their current therapy. It is not a replacement for the complete treatment regimen.
For individuals considering injectable therapy, medical assessment is essential. Treatment decisions depend on individual health circumstances, previous medication use, resistance testing, and the ability to attend scheduled appointments.
Several considerations are important when evaluating these options:
Eligibility assessment: Healthcare providers review viral load, treatment history, and HIV resistance results before selecting an injectable regimen.
Possible side effects: Injection-site pain, swelling, redness, headache, fever, and fatigue may occur. The type and frequency of side effects vary between medications.
Missed appointments: Delayed injections can reduce medication levels and increase the risk of treatment failure and drug resistance.
Follow-up testing: Regular viral load monitoring helps determine whether the treatment is maintaining HIV suppression.
Medication interactions: Other prescription medicines, supplements, and herbal products may affect how injectable HIV medications work.
Alternative arrangements: Individuals who cannot receive injections on schedule may require an oral medication plan under medical supervision.
Healthcare providers also explain what happens when injectable treatment is discontinued. Because some medicines remain in the body for months after the last injection, an appropriate alternative antiretroviral regimen must be started at the recommended time to reduce the risk of HIV developing resistance. Regular communication with the treatment team supports safe medication transitions and ongoing HIV management.